JAK-i on RA B-lymphocytes Tolerance and Disease Resolution Through JAK Signaling In Rheumatoid Arthritis

Institute of Hospitalization and Scientific Care (IRCCS)

Status: Enrolling

Conditions: Rheumatoid Arthritis

Treatments: Other: B lymphocyte profiling

Study type: Observational

Funder types: Other

Identifiers

NCT05754112

4109

Details and patient eligibility

About

The study will reveal the transcriptomic signature linked to the aberrant activation of B lymphocytes in RA identifying novel molecular potential targets for inflammation resolution and immune tolerance promotion. The combination with B lymphocytes phenotyping will dissect the impact of the identified genes on B lymphocyte maturation and activation in RA. Moreover, in vitro study on B lymphocyte cultures using selective JAK1 inhibition will reveal, at deeper level, its transcriptomic effect on RA B lymphocytes activation profile and phenotype, providing the discovery of new biomarkers of the loss of immunological tolerance, active disease and long lasting disease remission.

Enrollment: 50 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Signed Written Informed Consent. Before any study procedures are performed,subjects will have the details of the study described to them, and they will be given a written informed consent document to read. Then, if subjects consent to participate in the study, they will indicate that consent by signing and dating the informed consent document in the presence of trained study personnel.
2. Patients fulfilling classification criteria for Rheumatoid Arthritis (2010 ACR/EULARclassification criteria)
3. Age: 18-70 years
4. For preclinical cohort: Individuals with positivity for ACPA or IgM/IgA RF without clinical signs of arthritis, whose positivity is not related to other concomitant pathologic conditions.
5. For naive to treatment cohort: RA patients without previous exposure to conventional DMARDs or biologic/targeted synthetic-DMARDs.
6. For resistant to treatment cohort: RA patients with failure to previous conventionalDMARDs for inadequate response or side effects.
7. For remission RA cohort: RA patients in sustained clinical and ultrasound remission as stated in section 3.3.1.
8. For healthy control cohort: Healthy donors will be aged from 18 to 70 years.

Exclusion criteria

1. Severe and uncontrolled infections such as sepsis and opportunistic infections.
2. Patients who are currently included in any interventional clinical trial in RA.
3. RA patients in therapy with other biologics.
4. Healthy donors receiving anti-inflammatory drugs

Trial design

50 participants in 5 patient groups

ACPA/RFpos asyntomatic individuals

Description:

ACPA and/or RF positive individuals without active arthritis

Treatment:

Other: B lymphocyte profiling

Naive Active RA

Description:

Treatment-naive active RA (disease duration\<1 year)

Treatment:

Other: B lymphocyte profiling

Resistant RA

Description:

Active despite treatment RA

Treatment:

Other: B lymphocyte profiling

Remission RA

Description:

RA in sustained clinical and ultrasound remission

Treatment:

Other: B lymphocyte profiling

Control Group

Description:

Individuals asymptomatic for joint inflammation without ACPA/RF positivity

Treatment:

Other: B lymphocyte profiling